LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

LLY

1,075.18

+0.27%↑

JNJ

207.23

+0.6%↑

ABBV

227.72

+0.26%↑

UNH

325.11

-0.71%↓

AZN

91.53

+0.2%↑

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Gesloten

9.3 6.65

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.55

Max

9.36

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+56.86% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	8.3M 595M
Vorige openingsprijs	2.65
Vorige sluitingsprijs	9.3

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 dec 2025, 23:54 UTC

Belangrijke Marktbewegers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dec 2025, 19:08 UTC

Acquisities, Fusies, Overnames

Correction to Alphabet to Buy Intersect Article

22 dec 2025, 17:21 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dec 2025, 16:46 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dec 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dec 2025, 23:42 UTC

Marktinformatie

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dec 2025, 22:30 UTC

Winsten

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 21:37 UTC

Acquisities, Fusies, Overnames

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dec 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dec 2025, 20:52 UTC

Acquisities, Fusies, Overnames

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dec 2025, 20:09 UTC

Marktinformatie

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dec 2025, 19:56 UTC

Marktinformatie

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dec 2025, 19:49 UTC

Acquisities, Fusies, Overnames

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dec 2025, 19:23 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dec 2025, 19:23 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Precious Metals Climb to New Heights -- Market Talk

22 dec 2025, 18:45 UTC

Marktinformatie

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dec 2025, 18:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dec 2025, 18:23 UTC

Acquisities, Fusies, Overnames

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dec 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 dec 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

56.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.71 USD 56.86%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.